ArticleBMC neurology2026
[
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionFluorine 18 ([18F])–labeled DPA-714 binds to the translocator protein (TSPO), which can be used for monitoring activated glial cells during inflammatory process, and be potentially helpful for localizing the epileptogenic zone. In this study, we aimed to analyze the application of [18F] DPA-714 PET in preoperative evaluation of epilepsy, and to validate the results through surgical outcome and pathological results.
methodsPatients who underwent epilepsy surgery with both preoperative [18F]DPA-714 PET and 18F-fluorodeoxyglucose ([18F]FDG) PET were retrospectively reviewed. We visually compared [18F]DPA-714 PET, [18F]FDG PET findings and clinical data. The asymmetry index (AI) were also analyzed for both PET modalities. Pathological correlations with TSPO-positive findings ([18F]DPA-714 PET positive regions) were assessed using CD68 antibodies to identify microglial cells.
resultsEight patients were included in this study. All patients were seizure-free after one-year follow-up. Three patients underwent resection of regions that showed increased uptake on [18F]DPA-714 PET. These three patients had temporal lobe resection or temporal and opercular epileptogenic lesion resection, and their [18F]DPA-714 PET results showed hypermetabolism in ipsilateral mesial temporal lobe. We compared the microglial cells density in the gray matter and white matter separately, and found that microglial cells density was higher in the mesial temporal regions ([18F]DPA-714 PET positive regions) than in the anterior lateral temporal regions ([18F]DPA-714 PET negative regions) in both gray matter (p = 0.003) and white matter (p < 0.001). [18F]DPA-714 PET was more restricted than [18F]FDG PET in patients with temporal lobe epilepsy by visual analysis, whereas [18F]FDG PET showed greater asymmetry in frontal lobe epilepsy.
conclusionsThe [18F]DPA-714 PET positive regions correlated with increased microglial density, and it showed a different sensitivity in the recognition of the epileptogenic lesions in temporal and frontal lobe epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.